Ceribell Revolutionizes EEG Monitoring at the Bedside with AI

The revenue forecast for fiscal year 2026 has been raised to 28 to 31%
Canaccord raises the price target from $25 to $26 (Buy)
Andreas Zehetner
A. Zehetner
Reading Time: 2 minutes

Ceribell (CBLL) I now expect to reach an all-time high. The medical technology company develops a portable EEG system for rapid diagnosis and continuous monitoring of neurological disorders at the bedside. The focus is on AI-supported detection of non-convulsive status epilepticus (NCSE), which is often only visible in the EEG without obvious seizures. I appreciate that Ceribell not only provides quickly deployable single-use headbands but also the accompanying AI software, Clarity AI, for real-time data analysis, with recurring revenues increasing...

Read this article now with a free account.

Your benefits:

  • Every month, you can read 5 articles from the premium section for free.
  • Monthly 2 trial issues of the Trader newspaper for free.
  • Create a personal watchlist with an overview of news about your stock.
Trader Times
Free account
Here we go!
Image 1Image 2Image 3

Already registered? Log In